Resource utilisation, costs and clinical outcomes in non-institutionalised patients with Alzheimer’s disease: 18-month UK results from the GERAS observational study

Alan Lenox-Smith 1*, Catherine Reed 2, Jeremie Lebrec 3, Mark Belger 2 and Roy W. Jones 4

Abstract

Background: Alzheimer’s disease (AD), the commonest cause of dementia, represents a significant cost to UK society. This analysis describes resource utilisation, costs and clinical outcomes in non-institutionalised patients with AD in the UK.

Methods: The GERAS prospective observational study assessed societal costs associated with AD for patients and caregivers over 18 months, stratified according to baseline disease severity (mild, moderate, or moderately severe/severe [MS/S]). All patients enrolled had an informal caregiver willing to participate in the study. Healthcare resource utilisation was measured using the Resource Utilization in Dementia instrument, and 18-month costs estimated by applying unit costs of services and products (2010 values). Total societal costs were calculated using an opportunity cost approach.

Results: Overall, 526 patients (200 mild, 180 moderate and 146 MS/S at baseline) were recruited from 24 UK centres. Mini-Mental State Examination (MMSE) scores deteriorated most markedly in the MS/S patient group, with declines of 3.6 points in the mild group, 3.5 points in the moderate group and 4.7 points in the MS/S group; between-group differences did not reach statistical significance. Patients with MS/S AD dementia at baseline were more likely to be institutionalised (Kaplan–Meier probability 28% versus 9% in patients with mild AD dementia; p < 0.001 for difference across all severities) and had a greater probability of death (Kaplan–Meier probability 15% versus 5%; p = 0.013) at 18 months. Greater disease severity at baseline was also associated with concomitant increases in caregiver time and mean total societal costs. Total societal costs of £43,560 over 18 months were estimated for the MS/S group, versus £25,865 for the mild group and £30,905 for the moderate group (p < 0.001). Of these costs, over 50% were related to informal caregiver costs at each AD dementia severity level.

Conclusions: This study demonstrated a mean deterioration in MMSE score over 18 months in patients with AD. It also showed that AD is a costly disease, with costs increasing with disease severity, even when managed in the community: informal caregiver costs represented the main contributor to societal costs.

Keywords: Alzheimer’s disease, Clinical outcomes, Societal costs, AD dementia severity, Resource use, MMSE
Background
Alzheimer’s disease (AD) is the commonest cause of dementia representing 60–80% of all cases of dementia within Europe [1]. In the UK the Alzheimer’s Society has estimated that AD represents up to 62% of all cases of dementia [2]. Based on 2013 UK population data, the Alzheimer’s Society estimated the total age-standardised population prevalence of dementia to be 7% in those aged 65 years and over, equivalent to one in every 14 people in that age group [2]. At this rate of prevalence, approximately 850,000 individuals within the UK were expected to be affected by dementia in 2015 [2].

There have been several studies that have looked at the costs of dementia, most of which have used different methodology. Overall, and not surprisingly, there is general agreement that as the disease progresses the costs increase, especially once institutionalisation is required [3, 4]. Furthermore, informal care costs often form the majority of total costs [5]. As many of these and other studies use different methodologies ranging from multi-country clinical trial data and retrospective questionnaires, the robustness of the data has been questioned [6] and the difficulties of comparing studies has been highlighted [7].

Looking specifically at the UK, a recent analysis based on a model using estimates of prevalence, percentage of home versus care home usage, expenditure and quality of life, has estimated that the total cost of dementia to UK society is £26.3 billion per annum, representing an average annual cost of £32,250 per person [2]. Of this, approximately £4.3 billion, or 16%, is spent on healthcare costs, £10.3 billion (39%) on publicly and privately funded social care, and £0.1 billion (<1%) on other costs (including police time, research, advocacy and support by the voluntary sector). The remaining £11.6 billion (44%) represents the contribution of those unpaid family and friends who become carers for people with dementia [2]. The Alzheimer’s Society estimates that 670,000 people within the UK act as the primary, unpaid carer for an individual with dementia [8].

As the aforementioned studies lack robust, prospectively collected, local data, we performed an analysis of real-world UK data from the GERAS study. GERAS was a European prospective observational study that assessed the outcomes and societal costs associated with AD dementia for community-dwelling patients and their caregivers over at least 18 months. Patients were stratified according to their dementia severity at baseline into mild, moderate and moderately severe/severe disease groups, which broadly reflect the guidelines from NICE. The study design and baseline societal costs have been previously published [9]. The objective of the current paper is to describe the clinical outcomes in the UK in terms of cognition, institutionalisation and death, and to describe the costs seen in the different severity groups over an 18-month time period. The value of this study is its robustness, based on the prospective design, to gather national data on resource use and costs looking at patients with mild, moderate and severe AD dementia and the impact of this on their carers.

Methods
The GERAS study was an 18-month, multicentre, prospective, non-interventional, observational cohort study conducted in three European countries: the UK, France and Germany [8]. The study was designed to reflect routine care in patients with AD dementia. All treatment decisions were at the discretion of the treating physician, and were made following standard care procedures during the course of normal clinical practice; all treatments were permissible.

The focus of the current analysis is on those data collected from the UK. Inclusion criteria were community-dwelling patients, aged at least 55 years, presenting within the normal course of clinical care, diagnosed with probable AD dementia according to the National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer’s Disease and Related Disorders Association criteria [10], with a Mini-Mental State Examination (MMSE) score [11] of ≤26 points, and with an informal caregiver who was willing to participate in the study and undertake responsibility for the patient for at least 6 months of the year. Enrolled patients were stratified according to baseline disease severity as having mild (MMSE 21–26 points), moderate (MMSE 15–20 points) or moderately severe/severe AD dementia (MMSE ≤14 points). Ethical review board approval of the study was obtained according to UK regulations and written informed consent was obtained from all participants or their caregivers.

Sample size for the GERAS study was calculated based on the number of patients required to determine total costs associated with resource use in each country with sufficient precision, assuming 30% of patients would be lost during 18 months of follow-up and an equal enrolment of patients into the three AD dementia severity groups. Based on these assumptions, a minimum of 200 patients per AD dementia severity group per country was required for a 95% confidence interval ±10% of mean cost at 18 months (total 600 patients from the UK).

Data were collected for patients and caregivers at baseline, and at 6, 12 and 18 months during routine care visits. Collected data included demographics, current medications, patient and caregiver health/social care resource use (using the Resource Utilization in Dementia [RUD] instrument) [12], and MMSE score [11]. Other outcomes data collected in the GERAS study (at baseline and 18 months only, not reported in this manuscript) include the cognitive subscale of the Alzheimer’s Disease Assessment Scale [13], patient functioning and behaviour (Alzheimer’s Disease Co-operative Study Activities of Daily Living Inventory [14, 15]), health-related quality of life (for both
patients and caregivers, using the EuroQoL-5D instrument [16], caregiver working status and caregiver burden (Zarit Burden Interview [17]). The analysis reported here focuses on specific clinical outcomes (change in cognition [MMSE score], institutionalisation and death) and costs over the 18 months of the study.

**Resource utilisation**

The RUD instrument was used to measure healthcare resource utilisation by both patients and caregivers, and time spent on informal care by caregivers [12]. The RUD instrument, version RUD Complete 3.1, was administered by the physician, and answered by the primary informal caregiver, and the patient with AD when dementia severity permitted.

Resource use items collected included healthcare (outpatient visits [including: general practitioner, geriatrician, psychiatrist, neurologist, physiotherapist, occupational therapist, social worker and psychologist visits]), hospitalisations, emergency room visits; community care services (district nurse, home aid, food delivery, day care, transportation, other); changes to patient living accommodation (permanent, temporary, institutionalisation); caregiver working status (working for pay, missing work days); and primary caregiver time spent caring for the patient. Caregiver time was calculated as the number of hours spent:

- assisting the patient with basic activities of daily living (ADL) such as eating, bathing and dressing;
- assisting with instrumental ADL such as housework and shopping; and
- supervising the patient as required to prevent dangerous events such as risk of fire, and walking into the road if alone.

Information relating to patient medications, out-of-pocket expenses and additional financial support received, such as whether the patient or caregiver receives money from the government or an insurance company, was also collected during the interview with the caregiver. Data were collected from patients and caregivers at the baseline visit, and then during routine care visits at 6, 12 and 18 months (+/− 6 weeks [9]).

**Cost estimation**

Eighteen-month costs were estimated by applying unit costs of services and products (2010 values) to the health and social care resource use collected over the 18-month follow-up period. For resource-use items, full details of the unit costs applied and their sources have already been reported (see the Supplementary Material in Wimo et al. 2013 [9]).

Total societal costs were calculated using an opportunity cost approach taking into account productivity loss for working caregivers and lost leisure time for non-working caregivers. Costs were calculated for the month before each visit. Total societal costs were calculated by adding patient healthcare costs (including medications, hospitalisations and outpatient visits), patient social care costs (including community care services, structural adaptations to the home and extra financial support) and caregiver informal care costs (including time spent giving care and missing work). The number of hours for basic and instrumental ADL were used to calculate caregiver time, with 24 hours per day availability for total caregiver time assumed, but time spent on supervision applied a zero cost value. The unit cost of caregiver time for working caregivers was considered to be the value of lost productivity time based on the national average wage per UK population (a unit cost of £15.65 per hour at 2010 values; see the Supplementary Material in Wimo et al. 2013 [9]); for non-working caregivers, the unit cost of caregiver time was considered to be the value of lost leisure time based on 35% of the national average wage per UK population. Mean costs are reported for each baseline severity group, with bootstrapped 95% confidence intervals of the means.

The following imputation rules were applied for missing data: for institutionalised patients, mean monthly costs from the last visit were used for the period until institutionalisation, then monthly costs for institutionalisation (standard monthly cost of care with zero other costs) were used from institutionalisation up to 18 months; for patients who died, last observation carried forward was used, such that costs from the last known visit were extrapolated up to the date of death (no costs after death were computed). For those patients with other reasons for discontinuation, multiple imputation regression method [18] stratified by MMSE group was performed on missing costs. The list of factors used in the multiple imputation procedure was selected from those identified by Dodel et al. [19]. In addition to the above-described base case approach, three sensitivity analyses of costs were performed applying alternative imputation rules for missing data.

**Statistical analyses**

Demographics and baseline characteristics were summarised using descriptive statistics and were based on non-missing observations. In common with other clinical studies in AD [20–23], the change in MMSE score from baseline to 18 months was analysed using a mixed-model repeated measures analysis; this approach provides robust inference even in the presence of missing data. The model for the fixed effects included terms for AD dementia severity at baseline (classified as mild, moderate or moderately severe/severe), visit, and AD dementia severity at baseline-by-
visit interaction. As the changes in MMSE score (rather than absolute scores) were being analysed, the inclusion of baseline AD dementia severity level as a covariate negated the need for including baseline demographics in the model.

The Kaplan–Meier method was used to describe the probabilities of institutionalisation and death, and differences across baseline AD dementia severity groups for these time-to-event endpoints were tested using the log-rank test. Descriptive statistics were used to describe baseline variables and discontinuations.

Comparisons across baseline AD dementia severity groups were made using analysis of variance (ANOVA) for continuous variables or the Cochran–Mantel–Haenszel test for categorical variables.

All analyses were performed using SAS version 9.2 (SAS Institute, Cary, NC, USA).

**Results**

A total of 526 patients (200 mild, 180 moderate and 146 moderately severe/severe AD dementia) were recruited from 24 centres across the UK; baseline patient characteristics are shown in Table 1. Patient numbers at 18 months, when stratified according to baseline severity, are shown in Fig. 1. By the 18-month visit, 185 patients (35.2%) had discontinued the study due to institutionalisation (n = 94; 50.8% of discontinuations), death (n = 40; 21.6%) or other reasons (n = 51; 27.6%) e.g., lost to follow up, patient decision. Proportions of patients discontinuing increased with increasing baseline severity of AD dementia (Fig. 1).

**Clinical outcomes (MMSE)**

**Mean MMSE scores**

Over the 18-month duration of the GERAS study, a statistically significant deterioration in mean MMSE scores was observed (p < 0.001), which was most marked in the moderately severe/severe patient group (Fig. 2); declines in MMSE score were 3.6 points in the mild group, 3.5 points in the moderate group and 4.7 points in the moderately severe/severe group. However, differences in MMSE score changes between the groups did not reach statistical significance (p = 0.24).

**Severity level transitions**

A total of 330 patients had a MMSE score at 18 months (64.8%). Among patients assessed as having mild disease at baseline, 43.5% remained with mild disease, 36.7% transitioned from mild to moderate disease, 11.6% transitioned from mild to moderately severe/severe disease, and 8.2% had an MMSE score of >26. For those with moderate disease at baseline, 6.1% had scores indicating mild disease, 52.6% still had moderate disease and 41.2% progressed to moderately severe/severe disease. Among patients with moderately severe/severe disease at baseline, 2.9% had MMSE scores for moderate disease, but

| Table 1 | Patient demographics at baseline for the overall population stratified according to baseline AD dementia severity |
|---------|---------------------------------------------------------------------------------------------------------------|
| Characteristic                                      | Mild AD dementia (N = 200) | Moderate AD dementia (N = 180) | MS/S AD dementia (N = 146) | Overall (N = 526) | P-value* |
| Mean age in years [SD]                              | 78.9 [6.7]                  | 78.8 [8.1]                     | 77.6 [8.7]                  | 78.5 [7.8]       | 0.238    |
| Gender, n female [%]                                | 100 [50.0]                  | 94 [52.2]                     | 91 [62.3]                   | 285 [54.2]       | 0.061    |
| MMSE score, mean [SD]                               | 23.1 [1.6]                  | 17.8 [1.7]                    | 8.7 [4.5]                   | 17.3 [6.4]       | N/A      |
| Mean time since diagnosis in years [SD]             | 1.8 [2.1]                   | 2.0 [1.9]                     | 3.1 [2.2]                   | 2.2 [2.1]        | <0.001   |
| Caregiver lives with patient, n [%]                 | 156 [78.0]                  | 129 [71.7]                    | 122 [83.6]                  | 407 [77.4]       | 0.037    |
| Caregiver is spouse, n [%]                          | 144 [72.0]                  | 113 [62.8]                    | 98 [67.1]                   | 355 [67.5]       | 0.043b   |
| Caregiver mean age in years [SD]                    | 69.4 [11.70]                | 66.9 [11.77]                  | 68.7 [12.21]                | 68.3 [11.90]     | 0.099    |
| Caregiver gender, n female [%]                      | 129 [64.5]                  | 120 [66.7]                    | 76 [52.1]                   | 325 [61.8]       | 0.016    |
| AD medication use, n [%]                            | 31 [15.5]                   | 29 [16.1]                     | 19 [13.1]                   | 79 [15.0]        | –        |
| No AD medication                                    | 167 [83.5]                  | 144 [80.0]                    | 113 [77.9]                  | 424 [80.8]       | –        |
| Acetylcholinesterase inhibitor monotherapy          | 1 [0.5]                     | 5 [2.8]                      | 5 [3.4]                    | 11 [2.1]        | –        |
| Memantine monotherapy                              | 1 [0.5]                     | 2 [1.1]                      | 8 [5.5]                    | 11 [2.1]        | –        |

Percentages are based on the number of respondents (<1.0% missing)
AD Alzheimer’s disease, ANOVA analysis of variance, MMSE Mini-Mental State Examination, MS/S moderately severe/severe, N/A not applicable, SD standard deviation
*ANOVA p-value for continuous variables, Cochran–Mantel–Haenszel p-value for categorical variables between AD dementia severity groups
bP-value relates to the relationship of the caregiver to the patient
Fig. 1 Patient disposition at 18 months according to baseline AD dementia severity group. AD Alzheimer’s disease, MS/S moderately severe/severe.

Fig. 2 Change in MMSE score from baseline to 18 months stratified according to baseline AD dementia severity. AD, Alzheimer’s disease, MMSE Mini-Mental State Examination. Data are presented as least square means with 95% confidence intervals from mixed-model repeated measures analysis adjusted for baseline MMSE score. Change-from-baseline data missing for 0–9.0, 1–11.0 and 3.0–12.0% of patients across AD dementia severity groups at 6, 12 and 18 months, respectively.
the majority (97.1%) remained with moderately severe/severe disease (Fig. 3).

**Probability of institutionalisation**
There was a significant difference in the probability of institutionalisation between the three AD dementia severity groups ($p < 0.001$ for overall difference between severities). Patients with moderately severe/severe AD dementia at baseline were more likely to be institutionalised at 18 months (Kaplan–Meier probability estimate, 28.0%) than those with mild AD dementia (9.0%) at baseline (Table 2). Overall, the probability of being institutionalised by 18 months was 17.2%.

**Probability of death**
There were also significant differences between the three severity groups in terms of probability of death ($p = 0.013$). At 18 months, the probability of death in those with moderately severe/severe AD dementia at baseline was greater than in those with mild AD dementia (14.9% compared with 5.3%). The probability of death at 18 months overall was 8.2% (Table 2).

**Caregiver time**
At baseline, AD dementia severity was associated with increased mean total caregiver time ($p < 0.001$) and with increases in any of its components: time spent on basic or instrumental ADL or supervision (Fig. 4). Over the 18 months of the GERAS study, caregiver time spent on basic and instrumental ADL, together with time required for supervision, increased on average in all severity groups (Fig. 4). This increase from baseline was not significantly different across baseline AD dementia severity groups for any component of caregiver time or for overall caregiver time at 18 months.

**Societal costs**
The estimated mean total societal costs per patient over the 18-month duration of the study increased according to AD dementia severity, with total costs (bootstrapped 95% confidence intervals) of £43,560 (£39,059–£48,481) in patients with moderately severe/severe AD dementia compared with £25,865 (£23,444–£28,538) in those with mild and £30,905 (£28,539–£33,371) in those with moderate AD dementia ($p < 0.001$; Fig. 5). The largest component was the costs for caregiver informal care, which represented over 50% of costs for each AD dementia severity group.

As with total societal costs, there was a significant increase in caregiver informal care costs and patient social care costs associated with increases in AD dementia severity ($p < 0.001$), but patient healthcare costs were not significantly increased ($p = 0.624$). The results of the sensitivity analyses confirmed these base case findings (data not shown).
Discussion

This analysis from the GERAS observational study provides new information on clinical outcomes and societal costs associated with AD dementia in community-dwelling patients in the UK using prospective data. Deterioration in mean MMSE score over 18 months occurred at a similar rate in the mild and moderate AD dementia severity groups, with both showing a mean decrease of around 3.5 points over 18 months, and was greatest in the moderately severe/severe group (4.7 point decrease), although differences in MMSE score changes between the groups were not statistically significant. The probability of progression to institutionalisation or death increased in line with increases in baseline AD dementia severity.

Historically, the deterioration in MMSE score over time has been described as non-linear [24], as supported by a recently published, 18-month, randomised clinical trial in mild and moderate AD dementia [21]. In that study, MMSE scores in the mild and moderate groups receiving placebo decreased by an average of 2.4 and 5.8 points, respectively, over the 18-month period [21], and a similar decline in cognitive function was also seen in the same timeframe in a further study [22]. The results in our observational study did not demonstrate this trend. This disparity could be attributed to differences in study methodology, as randomised clinical trials are protocol-driven and patients are encouraged to stay within the trial; the greater patient retention rate observed in randomised clinical trials may mean that more information on patients’ MMSE scores over time is available. This difference in retention rates will be exaggerated by the inclusion of patients with more severe AD dementia within the GERAS study, where

![Fig. 4 Caregiver time for activities of daily living stratified by baseline AD dementia severity. AD Alzheimer's disease, ADL activities of daily living, MS/S moderately severe/severe. All values are based on data provided for the last month before each visit. The value beside each bar is the mean overall monthly caregiver time; this is not the sum of the three components of caregiver time because caregiver time was capped at 720 h/month. The n value is the number of respondents (0–9.0% missing). SD ranges observed across each individual endpoint at all time points and AD dementia severities were as follows: Overall time, 192–263 h; Supervision time, 120–269 h; Basic ADL, 59–138 h; Instrumental ADL, 83–150 h.](image-url)
dementia severity was related to study retention. It is also
known that the baseline demographics are different be-
tween the populations in these two types of studies.
In our analysis, 8.2% of patients with mild AD dementia
at baseline had an MMSE score >26 at 18 months, while
48.3% of patients demonstrated a decline in MMSE score,
with 11.6% transitioning from the mild to the moderately
severe/severe group. Although variability between individ-
ual patients is often observed [25], some of these patients
may not have had Alzheimer’s disease.
Our study demonstrated that patients with more severe
dementia had a higher rate of institutionalisation and were
more likely to die than those with less severe AD dementia.
This is not surprising, and is consistent with the findings
of a study conducted in 779 dementia patients recruited at
nine memory centres, which demonstrated that a shorter
time to institutionalisation was associated with lower cog-
nitive ability, lower functional ability and more neuropsy-
chiatric symptoms at baseline [26]. The greater the degree of
deterioration in cognitive ability noted during the first
3 months of this study, the shorter the observed time to
institutionalisation [26].
Consistent with baseline results [9], total societal costs in-
creased with increasing baseline AD dementia severity, and
caregiver informal care costs accounted for the highest pro-
portion of the component costs in GERAS at all levels of
severity. This latter finding potentially represents a large
cost saving in terms of formal healthcare costs. A UK sur-
vey of caregivers of people with dementia found that many
caregivers do not receive the support they need from health
and care services, with key services such as home support
for personal care, day care and provision of respite/time off
from caring being either not offered or funded privately
[27]. Carers should be provided with comprehensive sup-
port, including assistance with day-to-day caring, emotional
support and regular; planned access to respite to support
their own quality of life [4]. This is especially true given pre-
vious publications demonstrating an increase in caregiver
burden with severity of AD dementia [28, 29].
The costs of Alzheimer’s disease to society observed in
our study are substantial and were estimated to be ap-
proximately £26,000 for mild severity, £31,000 for moder-
ate severity and £44,000 for the moderately severe/severe
group per patient over an 18-month period. This trans-
lates to annual costs per patient of approximately £17,000
per year for mild, £21,000 for moderate and £29,000 for
moderate/severe severity groups. These are comparable to
the community figures calculated from the Alzheimer’s
Society which have been rounded to annual rates per pa-
tient of £26,000 for mild, £43,000 for moderate and
£55,000 for severe cases supporting the robustness of the
data despite some methodological differences [1].
Study strengths and limitations
Strengths of this study include that it was a large, prospective, observational study with a well-defined patient cohort, which collected longitudinal data over an 18-month period and assessed patients within the community across a range of disease severities. This study design would be expected to generate more reliable estimates of clinical outcomes, resource use and costs than either small cross-sectional studies [4, 30, 31] or retrospective database analyses, which may be susceptible to bias in data selection [32, 33].

The study also has limitations. Given the recruitment of patients principally from secondary care sites, it is possible that the sample is not truly representative of the overall AD dementia patient population. In addition, caregivers and participants were required to be sufficiently fit to participate in the study, which may represent a selection bias across all severities. It can also be challenging to make comparisons between studies due to different cost estimation methods, making analysis and interpretation of cost and resource data more difficult. Moreover, the 18-month duration of this study is still relatively short for accurately determining correlations between AD dementia severity and rate of cognitive decline or the probability of institutionalisation or death.

Conclusions
This observational study demonstrated a rate of deterioration in cognition of at least 3.5 points on the MMSE scale over the 18-month study period across all patient groups stratified according to baseline AD dementia severity. Increasing severity of disease was associated with increased patient institutionalisation and death, together with increased total societal costs. Our results show that even when managed within the community, AD dementia is a costly disease, with costs associated with informal caregivers representing the main contributing factor to societal costs. Given the greater costs associated with increasing severity of disease, any treatment that could help slow disease progression may have a significant impact on the costs of community-based care for patients with AD dementia.

Abbreviations
AD: Alzheimer’s disease; ADL: Activities of daily living; ANOVA: Analysis of variance; CI: Confidence interval; MMSE: Mini-mental state examination; MS/ S: Moderately severe/severe; NICE: National Institute for Health and Care Excellence; RUID: Resource utilization in dementia; SIGN: Scottish Intercollegiate Guidelines Network

Acknowledgements
The authors would like to acknowledge the participating investigators: Prof Roy W. Jones, RICE (The Research Institute for the Care of Older People), Royal United Hospital, Bath; Dr. Shamim Ruhu, St. Clements Hospital, Ipswich, Suffolk; Dr. Somaya Khalifa, Northgate Hospital, Great Yarmouth, Norfolk; Dr. Anushka Sivananthan, Bowmere Hospital, Chester; Dr. Adebayo Anjorin, The Berkshire Memory and Cognition Research Centre, Reading; Prof. Rohan Van der Putt, Warneford Hospital, Headington, Oxford; Dr. Paul Koranteng, Rushden Hospital, Rushden, Northamptonshire; Dr. John Mulinga, Lancashire Care NHS Foundation Trust, Heysham, Lancashire; Dr. David Findlay, Royal Dundee Liff Hospital, Dundee; Dr. Sarah Baillon, Leicestershire Partnership NHS Trust, Leicester; Dr. Alasdair Lawrie, Royal Cornhill Hospital, Aberdeen; Dr. Elizabeth Sampson, St Ann’s Hospital, Tottenham, London; Dr. Nicholas Bass, Newham Centre for Mental Health, London; Dr. Lucy Elas, The Beacon Centre, Ramsgate, Kent; Dr. Steve Pearson, Devon Partnership NHS Trust, Ivybridge, Devon; Prof. John Starr, Royal Victoria Hospital, Edinburgh; Dr. Derek Brown, Stobhill Hospital, Glasgow; Dr. Peter Bowie, Grenoside Grange Hospital, Sheffield, Yorkshire; Dr. Biswadeep Majumdar, South Sefton Neighbourhood Centre, Liverpool, Merseyside; Dr. Katie Kelly, Charington Lane Hospital, Cheltenham, Gloucestershire; Dr. Steve Simpson, Yeatman Hospital, Sherborne, Dorset; Dr. George El-Nimr, Harplands Hospital, Harptfields, Stoke-on-Trent; Dr. Darren Reynolds, Carleton Clinic, Carlisle, Cumbria; Dr. Katrina Young, St Mary’s Surgery, Ely, Cambridgeshire. The authors would also like to acknowledge Dr. Sarah Birch and Dr. Claire Lavin of Rx Communications, Mold, UK for medical writing assistance funded by Eli Lilly and Company.

Funding
This study was funded by Eli Lilly and Company.

Availability of data and materials
The data will not be shared as they are proprietary information.

Authors’ contributions
ALS was involved in the design of the study and the drafting of the manuscript. CR was involved in the design of the study and assisted in the drafting of the manuscript. JL performed the statistical analysis, and assisted in the drafting and reviewing of the manuscript. MB was involved in the design of the study and the statistical analysis, and assisted in the drafting of the manuscript. RWJ was involved in the conduct of the study, as a member of the study advisory board, and in the writing and review of the overall manuscript. All authors read and approved the final manuscript.

Competing interests
The GERAS study was fully funded by Eli Lilly and Company. ALS, CR and MB are employees and minor shareholders of Eli Lilly and Company. JL works as a full-time contractor for Eli Lilly. RWJ has received honoraria and consultancy fees from Eli Lilly and other companies involved in research to find new treatments for AD; his institution received research funding for participation in the GERAS study.

Consent for publication
Not applicable.

Ethics approval and consent to participate
Ethical review board approval of the study was obtained according to UK regulations and written informed consent was obtained from all participants or their caregivers.

National ethics committee approvals obtained: UK: NHS National Research Ethics Service, South West 5 REC (reference 10/H0107/43); Scotland A Research Ethics Committee (reference number 10/MRE0/63).  

Author details
1Eli Lilly and Company, Basingstoke, UK. 2Eli Lilly and Company, Erl Wood, Windleshay, UK. 3Eli Lilly and Company, Bad Homburg, Germany. 4RICE (The Research Institute for the Care of Older People), Royal United Hospital, Bath, UK.

Received: 9 May 2016 Accepted: 16 November 2016
Published online: 25 November 2016

References
1. Organisation for Economic Co-operation and Development (OECD). Tackling dementia with big data. April 2015. http://www.oecd.org/ █/828/tackling_dementia_with_big_data.html. Accessed 17 Feb 2016.
2. Alzheimer’s Society. Dementia UK: update. 2014. http://www.alzheimers.org. uk/site/scripts/download_info.php?FileID=2323. Accessed 17 Feb 2016.
3. Wubker A, Zwakhalen SMG, Challis D, Suohon R, Karlsson S, Zabalegui A, et al. Costs of care for people with dementia just before and after nursing
home placement: primary data from eight European countries. Eur J Health Econ. 2015;16(7):689–707.

4. Mesterton J, Wimo A, By A, Langsworth S, Winblad B, Jönsson L. Cross sectional observational study on the societal costs of Alzheimer's disease. Curr Alzheimer Res. 2010;7(4):358–67.

5. Jönsson L, Wimo A. The cost of dementia in Europe: a review of the evidence and methodological considerations. Pharmacoeconomics. 2009;27(3):391–403.

6. Wimo A, Ballard C, Brayne C, Gauthier S, Handels R, Jones RW, et al. Health economic evaluation of treatments for Alzheimer's disease: impact of new diagnostic criteria. J Intern Med. 2014;275(3):304–16.

7. Quentin W, Reidel-Heller SG, Luppa M, Rudolph A, König HH. Cost-of-illness studies of dementia: a systematic review focusing on stage dependency of costs. Acta Psychiatr Scand. 2010;121(4):243–59.

8. Alzheimer's Society. Dementia 2013: The hidden voice of loneliness. 2013. http://www.alzheimers.org.uk/site/scripts/download_info.php?fileID=1677. Accessed 17 Feb 2016.

9. Wimo A, Reed CC, Dodel R, Belger M, Jones RW, Happich M, et al. The GERAS Study: a prospective observational study of costs and resource use in community dwellers with Alzheimer's disease in three European countries – study design and baseline findings. J Alzheimers Dis. 2013;36(2):385–90.

10. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS–ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology. 1984;44(7):939–44.

11. Folstein MF, Folstein SE, McHugh PR. 'Mini-mental state': a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189–98.

12. Wimo A, Wetterholm A-L, Mastey V, Winblad B. Evaluation of the healthcare resource utilization and caregiver time in anti-dementia drug trials. In: Wimo A, Jönsson B, Karlsson G, Winblad B, editors. Health economics of dementia. Wiley & Sons; 1987.

13. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer disease. The Alzheimer Disease Cooperative Study. Detailed assessment of activities of daily living in moderate to severe Alzheimer disease. J Int Neuropsychol Soc. 2005;11(4):446–53.

14. Galasko D, Schmitt F, Thomas R, Ernesto C, Thomas R, Grundman M, et al. Predictors of institutionalization in dementia: a three year longitudinal study. J Alzheimers Dis. 2014;40(4):221–6.

15. Newbromer L, Chamberlain R, Borthwick R, Baxter M, Glendinning C. A road less rocky – supporting carers of people with dementia. 2013. https://carers.org/article/road-less-rocky-supporting-carers-people-dementia. Accessed 17 Feb 2016.

16. Vellas B, Hausner L, Fröhlich L, Cantit C, Gardette V, Reynish E, et al. Progression of Alzheimer disease in Europe: data from the European ICTUS study. Curr Alzheimer Res. 2012;9(8):902–12.

17. Doody RS, Raman R, Farlow M, Iwatsubo T, Vellas B, Joffe S, Kieburtz K, He F, et al. Determinants of societal costs in Alzheimer's disease. N Engl J Med. 2013;369(4):341–50. doi:10.1056/NEJMoa1210951.

18. Rubin DB. Multiple imputation for nonresponse in surveys. New York: John Wiley and Sons; 1987.

19. Doody RS, Thomas RG, Farlow M, Ivatsubo T, Vellas B, Joffe S, Alzheimer's Disease Cooperative Study Steering Committee, Siemers E, Sethuraman G, Mohs R. Semagacestat Study Group. A phase 3 trial of semagacestat for treatment of Alzheimer's disease. N Engl J Med. 2013;369(4):341–50. doi:10.1056/NEJMoa1210951.

20. Doody RS, Thomas RG, Farlow M, Ivatsubo T, Vellas B, Joffe S, Alzheimer's Disease Cooperative Study Steering Committee; Solanezumab Study Group, et al. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. N Engl J Med. 2014;370(4):311–21.

21. Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M, et al. Bapineuzumab 301 and 302 Clinical Trial Investigators. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. N Engl J Med. 2014;370(4):322–33.

22. Siemers ER, Sundell KL, Carlson C, Case M, Sethuraman G, Liu-Siefert H, Jönsson L, Wimo A, et al. Phase 3 solanezumab trials: secondary outcomes in mild Alzheimer's disease patients. Alzheimers Dement. 2016;12(11):20–20.

23. Ashford JW, Schmitt FA. Modeling the time-course of Alzheimer dementia. Curr Psychiatry Rep. 2001;3(1):20–8.

24. Marioni RE, Chatfield M, Brayne C, Matthews FE, Medical Research Council Cognitive Function and Ageing Study Group. The reliability of assigning individuals to cognitive states using the mini mental-state examination: a population-based prospective cohort study. BMC Med Res Methodol. 2011:11:27.

25. Brodaty H, Conners MH, Xu J, Woodward M, Ames D, PRIME study group. Determinants of institutionalization in dementia: a three year longitudinal study. J Alzheimers Dis. 2014;40(4):221–6.

26. Fröhlich L, Tejada-Baillon R, Borthwick R, Baxter M, Glendinning C. A road less rocky – supporting carers of people with dementia. 2013. https://carers.org/article/road-less-rocky-supporting-carers-people-dementia. Accessed 17 Feb 2016.

27. Dodel R, Belger M, Dell'Agnello G, Wimo A, Argimon JM, Bruno G, et al. Caregiver burden in Alzheimer's disease: differential associations in adult-child and spousal caregivers in the GERAS observational study. Dement Geriatr Cogn Dis Extra. 2014;4(1):51–64.

28. Galasko D, Chauvin P, Bellanger MM. Evaluation of full costs of care for patients with Alzheimer's disease in France: the predominant role of informal care. Health Policy. 2014;116(1):114–22.

29. Darbà J, Kasksen L, Lacey L. Relationship between global severity of patients with Alzheimer's disease and costs of care in Spain; results from the co-dependence study in Spain. Eur J Health Econ. 2015;16(8):895–905.

30. Ward RA, Brier ME. Retrospective analyses of large medical databases: what do they tell us? J Am Soc Nephrol. 1999;10(2):x29–32.

31. Brüggenjürgen B, Andensohn F, Ezatt N, Lacey L, Willich S. Medical management, costs, and consequences of Alzheimer's disease in Germany; an analysis of health claims data. J Med Econ. 2015;18(6):466–73.